IN THE NEWS
We recently appeared in:
St. Louis Business Journal:
St. Louis Post Dispatch:
Inside Digital Health:
Kingdom Capital Collaborates with Washington University School of Medicine to Launch Augmented Intelligence Company PercayAI
ST. LOUIS (October 10, 2019) – Values-driven investment firm, Kingdom Capital, today announced the launch of PercayAI, an augmented intelligence software company that helps researchers develop new drugs more quickly and successfully.
The first product available from PercayAI is CompBio™, software co-developed with the Genome Technology Access Center at the McDonnell Genome Institute (GTAC@MGI) at Washington University School of Medicine in St. Louis. Using a unique combination of contextual language processing and artificial intelligence, CompBio can mimic the thought processes of biological science experts, rapidly identifying non-obvious relationships within complex, -omic and multi-omic biological data sets.
CompBio’s interface uses an intuitive, interactive 3D format that allows researchers to easily view all the information specific to their biological paradigm, helping scientists to have a greater understanding of the biology driving their research. During development, CompBio’s capabilities were validated by the GTAC through testing with more than 40 laboratories, including one led by microbiome research pioneer and 2018 Copley Medal recipient Dr. Jeffrey Gordon of Washington University, resulting in the first of several upcoming publications using CompBio in peer reviewed journal articles.
“PercayAI represents a foundational suite of technologies to further Kingdom Capital’s mission to benefit patients and their families,” said Scott Glover, President Health & Medical sector. “As a values-driven investment firm, our investments address unmet or under-resourced needs, and PercayAI will play an important role in helping to accelerate drug discovery, leading to new medicines and better patient outcomes faster.”
Utilization of COMPBIO was recently described in a PNAS publication from the Gordon Lab at Washington University entitled 'Mechanisms by which sialylated milk oligosaccharides impact bone biology in a gnotobiotic mouse model of infant undernutrition.' (May 28th, 2019 https://doi.org/10.1073/pnas.1821770116 )
Based on differential expression of 164 genes, three key cellular and molecular pathway findings (eosinophil status, tuft cell increases, and succinate pathway activity) were predicted by COMPBIO’s Biological Knowledge Generation Engine, and subsequently validated in the laboratory. These novel findings may provide a mechanistic linkage between bone formation, the gut microbiota and cellular signaling within the intestinal mucosa.